3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
4
Plasma cell
1
Other hematologic neoplasm
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
54
Leukemia, B-Cell
7
Lymphoma, Mantle-Cell
5
Leukemia
5
Lymphoma
4
Lymphoma, Non-Hodgkin
3
Lymphoma, Large B-Cell, Diffuse
3
Recurrence
2
Leukemia, Prolymphocytic
2
Hematologic Neoplasms
2
Waldenstrom Macroglobulinemia
1
Multiple Myeloma
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Lymphatic Diseases
1
Leukemia, Hairy Cell
1
Hodgkin Disease
1
Heart Failure
1
Glioblastoma
1
Chromosome 17 deletion
1
Burkitt Lymphoma
1
Anemia, Hemolytic, Autoimmune
1
Interventions
fludarabine phosphate
52
Cyclophosphamide
52
Peripheral Blood Stem Cell Transplantation
50
Rituximab
47
Mycophenolic Acid
34
Whole-Body Irradiation
33
Tacrolimus
26
Cyclosporine
25
Busulfan
23
Etoposide
21
Filgrastim
19
Methotrexate
18
Melphalan
18
Antilymphocyte Serum
18
Radiotherapy
15
Bortezomib
15
Sirolimus
12
Lenalidomide
11
ibrutinib
9
Flow Cytometry
9
Cyclosporins
9
Everolimus
8
Dexamethasone
8
Carboplatin
8
sargramostim
7
Polymerase Chain Reaction
7
Methylprednisolone
7
Indium
7
Cytarabine
7
idelalisib
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Waldenstrom Macroglobulinemia
×
acalabrutinib
×
Other hematologic neoplasm
×
Clear all
NCT02362035
2026-05-13
KEYNOTE145
Acerta Pharma BV
Phase 1/2
Completed
161 enrolled
29 charts